March 27, 2018
KEY POINTS Zejula plus Keytruda improved the clinical benefits significantly in difficult-to-treat ovarian cancer patients than any one of them ...
Access articles & resources worth up to US $4, 000 per month.
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review
New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status
Ovarian Cancer Drug Zejula Shows Historical Results in Combination for Hard-to-Treat Cancer
Merck’s New Class of Drugs Shows Potential against Resistant Cancers
7 New Ideas to Start a Healthcare Business in India (2018)
Pharma Patents: Can India Reward Incremental Innovation?